Antagonizing the IL-17–receptorinteraction can abrogate the inflammatory overreaction of this cytokinein a pathogenic setting.1 The potentialapplications of IL17-directed drugs could go well beyond the above-mentionedindications, e.g., multiple sclerosis (MS), Alzheimer’s disease,or ischemic brain injury; however, they are limited by the mAb natureof the currently available drugs.2 This evidence concerns the gene IL17A and early-onset autosomal dominant Alzheimer disease.